Free tool
Drug Trial Radar: Cardiovascular and metabolic
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
97
Active, not recruiting, industry sponsors, Cardiovascular and metabolic, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting167
- Completed1,732
97 trials
Showing 1 to 25, recently updated first.
- Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic CancerActive, not recruiting
Aulos Bioscience, Inc.Industry
NCT05267626 · 159 participants (planned) · Start Apr 4, 2022 · Primary completion Feb 28, 2027
Drug: AU-007; Aldesleukin and 2 more · For: Advanced Solid Tumor; Metastatic Cancer; Cutaneous Melanoma and 1 more
Sites: Miami, Florida; Grand Rapids, Michigan; Minneapolis, Minnesota · 17 sites in all
- A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DMPivotal-lookingActive, not recruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT06845202 · 105 participants · Start Mar 3, 2025 · Primary completion Aug 31, 2027
Drug: ALN-4324; Placebo · For: Obese or Overweight Healthy Volunteers; Type 2 Diabetes Mellitus (T2DM)
Sites: Montclair, California; Washington D.C., District of Columbia; Miami, Florida · 22 sites in all
- Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPDPivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05612035 · 129 participants · Start Mar 16, 2023 · Primary completion Apr 9, 2026
Drug: Frespaciguat; Placebo · For: Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease
Sites: San Francisco, California; Aurora, Colorado; Sebring, Florida · 85 sites in all
- A Study of Setmelanotide in Patients With Prader-Willi SyndromeActive, not recruiting
Rhythm Pharmaceuticals, Inc.Industry
NCT06772597 · 18 participants · Start Mar 4, 2025 · Primary completion Nov 3, 2026
Drug: Setmelanotide · For: Prader-Willi Syndrome; Obesity; Hyperphagia
Sites: Gainesville, Florida
- A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes MellitusActive, not recruiting
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
NCT07465224 · 24 participants · Start Jan 15, 2026 · Primary completion May 28, 2027
Drug: ALN-4324; Placebo · For: Type 2 Diabetes Mellitus (T2DM)
Sites: Chula Vista, California
- A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or OverweightPivotal-lookingActive, not recruiting
Boehringer IngelheimBoehringer Ingelheim
NCT07662122 · 345 participants · Start Jun 30, 2026 · Primary completion Jun 26, 2027
Drug: BI 3034701; Placebo matching BI 3034701 · For: Obesity; Overweight
Sites: Birmingham, Alabama; West Hills, California; Miami, Florida · 55 sites in all
- A Study of CX11 Tablets in Patients With Type 2 Diabetes MellitusPivotal-lookingActive, not recruiting
Corxel PharmaceuticalsIndustry
NCT07340320 · 251 participants · Start Feb 6, 2026 · Primary completion Apr 8, 2027
Drug: CX11 · For: Type II Diabetes Mellitus
Sites: Birmingham, Alabama; Huntsville, Alabama; Cerritos, California · 44 sites in all
- Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 DiabetesActive, not recruiting
SanofiSanofi (SNY)
NCT06791291 · 5 participants · Start Jul 25, 2025 · Primary completion Mar 6, 2028
Drug: Teplizumab · For: Type 1 Diabetes Mellitus
Sites: Ichikawa, Japan; Maebashi, Japan; Sapporo, Japan · 15 sites in all
- Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic RetinopathyActive, not recruiting
AbbVieAbbVie (ABBV)
NCT05296447 · 103 participants · Start Apr 4, 2022 · Primary completion Jun 2031
Drug: Standard of Care; Aflibercept · For: Diabetic Retinopathy, DR
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 20 sites in all
- A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerPivotal-lookingActive, not recruiting
Agenus Inc.Industry
NCT05608044 · 234 participants · Start Nov 30, 2022 · Primary completion Sep 2027
Drug: Botensilimab; Balstilimab and 1 more · For: Metastatic Colorectal Cancer
Sites: Scottsdale, Arizona; Duarte, California; Los Angeles, California · 65 sites in all
- A Study of PF-08653945 and PF-08653944 in Adults With Overweight or ObesityPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT07575932 · 940 participants · Start May 11, 2026 · Primary completion Aug 4, 2027
Drug: PF-08653945; PF-08653944 and 1 more · For: Overweight; Obesity; Overweight and/or Obesity and 5 more
Sites: Sun City West, Arizona; Canoga Park, California; Fountain Valley, California · 63 sites in all
- A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)Pivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06836609 · 118 participants · Start Apr 28, 2025 · Primary completion Aug 17, 2027
Drug: ALN-CIDEB; Placebo · For: Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis
Sites: Chandler, Arizona; Tucson, Arizona; London, United Kingdom · 4 sites in all
- A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial HypertensionActive, not recruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT03492177 · 63 participants · Start Jul 23, 2018 · Primary completion Mar 28, 2022
Drug: selexipag (Uptravi) · For: Pulmonary Arterial Hypertension
Sites: Aurora, Colorado; Iowa City, Iowa; Seattle, Washington · 34 sites in all
- Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeActive, not recruiting
Corcept TherapeuticsIndustry
NCT03604198 · 125 participants · Start May 7, 2018 · Primary completion Dec 2026
Drug: relacorilant · For: Cushing Syndrome
Sites: Phoenix, Arizona; Stanford, California; Torrance, California · 48 sites in all
- Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)Pivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT06111586 · 197 participants · Start Dec 11, 2023 · Primary completion Apr 28, 2027
Drug: Frexalimab; Placebo and 1 more · For: Type 1 Diabetes Mellitus
Sites: San Francisco, California; Aurora, Colorado; Gainesville, Florida · 79 sites in all
- A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes MellitusPivotal-lookingActive, not recruiting
Arrowhead PharmaceuticalsIndustry
NCT06700538 · 190 participants · Start Dec 4, 2024 · Primary completion Oct 15, 2027
Drug: ARO-INHBE; Placebo and 1 more · For: Obesity
Sites: Camberwell, Australia; Charlestown, Australia; Maroochydore, Australia · 15 sites in all
- A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06857955 · 396 participants · Start Mar 26, 2025 · Primary completion Sep 17, 2026
Drug: QCZ484 · For: Hypertension
Sites: Andalusia, Alabama; Huntsville, Alabama; Saraland, Alabama · 72 sites in all
- A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06151964 · 166 participants · Start Sep 29, 2023 · Primary completion Jan 29, 2027
Drug: AZD9550; placebo and 1 more · For: Overweight and Obesity
Sites: Graz, Austria; Vienna, Austria; Surrey, Canada · 15 sites in all
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)Pivotal-lookingActive, not recruiting
Insmed IncorporatedIndustry
NCT05649748 · 91 participants · Start Mar 7, 2023 · Primary completion Dec 31, 2026
Drug: Treprostinil Palmitil; Placebo · For: Pulmonary Arterial Hypertension
Sites: Jacksonville, Florida; Tampa, Florida; Chicago, Illinois · 45 sites in all
- A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have HypercholesterolemiaPivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07477704 · 438 participants · Start Jun 17, 2026 · Primary completion Dec 29, 2026
Drug: Alirocumab · For: Hypercholesterolemia
Sites: Anniston, Alabama; Cullman, Alabama; Anaheim, California · 34 sites in all
- A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway ImpairmentPivotal-lookingActive, not recruiting
Rhythm Pharmaceuticals, Inc.Industry
NCT06239116 · 111 participants · Start Mar 5, 2024 · Primary completion May 7, 2027
Drug: Part A: RM-718 or placebo (matched to specific RM-718 dose cohort); Part B: RM-718 or placebo (matched to specific RM-718 dose cohort) and 2 more · For: Hypothalamic Obesity; Prader-Willi Syndrome; PWS
Sites: Birmingham, Alabama; Chicago, Illinois; Boston, Massachusetts · 7 sites in all
- A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 DiabetesActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05791201 · 7 participants · Start May 16, 2023 · Primary completion Mar 12, 2027
Drug: VX-264 · For: Type 1 Diabetes
Sites: Miami, Florida; Chicago, Illinois; Boston, Massachusetts · 16 sites in all
- A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07215559 · 200 participants (planned) · Start Oct 16, 2025 · Primary completion Mar 2027
Drug: Macupatide; Eloralintide and 2 more · For: Obesity; Overweight; Diabetes Mellitus, Type 2
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 42 sites in all
- A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin AmyloidosisActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT06260709 · 88 participants (planned) · Start Feb 20, 2024 · Primary completion Feb 29, 2028
Drug: NNC6019-0001 · For: Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Sites: Phoenix, Arizona; Los Angeles, California; Stanford, California · 38 sites in all
- Study of Re-Treatment With ALXN2220 in Patients With ATTR-CMActive, not recruiting
Neurimmune AGIndustry
NCT07213583 · 35 participants (planned) · Start Aug 28, 2025 · Primary completion Oct 31, 2026
Drug: ALXN2220 · For: Amyloid Transthyretin Cardiomyopathy
Sites: Créteil, France; Rennes, France; Toulouse, France · 6 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.